Table 3. Data for Each Identified Interaction on the PS-Matched Validation Cohort, the Total PS-Matched Cohort, and the Crude Cohort.
Interaction | OR (95% CI) | ||
---|---|---|---|
Propensity Score Matched Cohort | Crude Cohort Total | ||
Validation | Total | ||
Hemiplegia or paraplegiaa,b | 5.19 (4.37-6.18) | 5.35 (4.74-6.05) | 18.42 (17.38-19.52) |
No solid tumor and WLa,c,d | 3.49 (2.89-4.22) | 3.50 (3.06-4.01) | 30.23 (28.72-31.82) |
CHF and stage I-IV RDa,c,e | 3.40 (2.99-3.86) | 3.45 (3.15-3.77) | 24.66 (23.66-25.71) |
Other ND and CHFa,c | 2.79 (2.19-3.55) | 2.45 (2.06-2.92) | 38.15 (35.51-40.99) |
No HPTN C and CHF and stage I-V RDa,c | 2.75 (2.45-3.08) | 2.76 (2.54-2.99) | 20.36 (19.62-21.13) |
Lymphomaa,f | 2.04 (1.66-2.52) | 1.93 (1.66-2.23) | 2.77 (2.57-3.00) |
Abbreviations: CHF, congestive heart failure; HPTN C, complicated hypertension; METS, metastatic cancer; ND, neurologic disorders; OR, odds ratio; PS, propensity score; RD, renal disease; WL, weight loss.
Charlson cormorbidity index.
Also identified, hemiplegia or paraplegia and no solid tumor with METS, or no blood loss anemia, or no liver disease, or no psychoses.
Elixhauser index.
Also identified, WL and no solid tumor with or without METS.
Also identified, stage I to IV RD and no solid tumor with METS.
Also identified, lymphoma and no solid tumor with METS.